Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Metagenomi Therapeutics, Inc.MGX · Entity 7270 | See Remarks | September 08, 2026 | September 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Metagenomi Therapeutics, Inc.
Report date September 08, 2026 · Filed September 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 126,133 |
Reported balance
After 2026-09-08 transaction · row 1
1 source rowRow 1 · 2026-09-08 · Sale · Disposed 358 · Balance 126,133 F1: These shares of common stock were automatically sold for the purpose of satisfying the Reporting Person's tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person on each of April 1, 2024 and April 1, 2025, and does not represent a volitional trade by the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares of common stock were automatically sold for the purpose of satisfying the Reporting Person's tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person on each of April 1, 2024 and April 1, 2025, and does not represent a volitional trade by the Reporting Person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 08, 2026 Filed Sep 10, 2026 19:47 UTC | Metagenomi Therapeutics, Inc. MGX · Entity 7270 | SaleCommon Stock | 358 | $1.16 | $414.71 |
DisclosureSEC source: 0001193125-26-387816 · ownership.xml · nonDerivative · entry 1 Wein Matthew · CIK 0002009713 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,133 F1 · kind: These shares of common stock were automatically sold for the purpose of satisfying the Reporting Person's tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person on each of April 1, 2024 and April 1, 2025, and does not represent a volitional trade by the Reporting Person. Read SEC document |
| June 05, 2026 Filed Jun 10, 2026 15:19 UTC | Metagenomi Therapeutics, Inc. MGX · Entity 7270 | SaleCommon Stock | 558 | $1.30 | $724.84 |
DisclosureSEC source: 0001193125-26-265326 · ownership.xml · nonDerivative · entry 1 Wein Matthew · CIK 0002009713 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,491 F1 · kind: These shares of common stock were automatically sold for the purpose of satisfying the Reporting Person's tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person on each of April 1, 2024 and April 1, 2025, and does not represent a volitional trade by the Reporting Person. F2 · balance_after: Includes 1,500 shares acquired under the Company's employee stock purchase plan ("ESPP") on May 29, 2026. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 18:00 UTC | Metagenomi Therapeutics, Inc. MGX · Entity 7270 | GrantStock Option (Right to Buy) · Derivative | 68,000 | $0.00 Strike: $1.34 | $0.00 |
DisclosureSEC source: 0001193125-26-141914 · ownership.xml · derivative · entry 2 Wein Matthew · CIK 0002009713 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,000 Underlying: Common Stock · 68,000 shares Expires 2036-03-31 F2 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on April 1, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 18:00 UTC | Metagenomi Therapeutics, Inc. MGX · Entity 7270 | GrantCommon Stock | 11,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-141914 · ownership.xml · nonDerivative · entry 1 Wein Matthew · CIK 0002009713 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,549 F1 · shares: These shares represent restricted stock units ("RSUs"). 25% of the RSUs shall vest on June 5, 2027, with the remainder vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date. Read SEC document |
| March 05, 2026 Filed Mar 9, 2026 21:16 UTC | Metagenomi Therapeutics, Inc. MGX · Entity 7270 | SaleCommon Stock | 482 | $1.60 | $771.20 |
DisclosureSEC source: 0001193125-26-098821 · ownership.xml · nonDerivative · entry 1 Wein Matthew · CIK 0002009713 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,549 F1 · kind: These shares of common stock were automatically sold for the purpose of satisfying the Reporting Person's tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person on each of April 1, 2024 and April 1, 2025, and does not represent a volitional trade by the Reporting Person. Read SEC document |
| December 05, 2025 Filed Dec 8, 2025 18:51 UTC | Metagenomi Therapeutics, Inc. MGX · Entity 7270 | SaleCommon Stock | 199 | $1.77 | $352.61 |
DisclosureSEC source: 0001193125-25-310958 · ownership.xml · nonDerivative · entry 1 Wein Matthew · CIK 0002009713 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,031 F1 · kind: These shares of common stock were automatically sold for the purpose of satisfying the Reporting Person's tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person on April 1, 2024, and does not represent a volitional trade by the Reporting Person. Read SEC document |
| December 01, 2025 Filed Dec 1, 2025 23:37 UTC | Metagenomi Therapeutics, Inc. MGX · Entity 7270 | GrantCommon Stock | 96,000 | $1.60 | $153,600.00 |
DisclosureSEC source: 0001193125-25-304177 · ownership.xml · nonDerivative · entry 2 Wein Matthew · CIK 0002009713 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,230 F3 · kind: These shares represent RSUs. 50% of the RSUs shall vest on December 5, 2026, with the remainder vesting on December 5, 2027, subject to the Reporting Person's continued service with the Issuer on each such vesting date. Read SEC document |
| September 05, 2025 Filed Dec 1, 2025 23:37 UTC | Metagenomi Therapeutics, Inc. MGX · Entity 7270 | SaleCommon Stock | 199 | $1.81 | $360.19 |
DisclosureSEC source: 0001193125-25-304177 · ownership.xml · nonDerivative · entry 1 Wein Matthew · CIK 0002009713 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,230 F1 · kind: These shares of common stock were automatically sold for the purpose of satisfying the Reporting Person's tax withholding obligations upon the vesting of certain restricted stock units ("RSUs") granted to the Reporting Person on April 1, 2024, and does not represent a volitional trade by the Reporting Person. F2 · balance_after: Includes 1,359 shares acquired under the Company's employee stock purchase plan ("ESPP") on May 30, 2025 and 1,377 shares acquired under the Company's ESPP on November 28, 2025. Read SEC document |
| June 06, 2025 Filed Jun 9, 2025 23:04 UTC | Metagenomi Therapeutics, Inc. MGX · Entity 7270 | SaleCommon Stock | 199 | $1.75 | $348.25 |
DisclosureSEC source: 0000950170-25-083963 · ownership.xml · nonDerivative · entry 1 Wein Matthew · CIK 0002009713 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,693 F1 · kind: These shares of common stock were automatically sold for the purpose of satisfying the reporting person's tax withholding obligations upon the vesting of certain restricted stock units granted to the reporting person on April 1, 2024, and does not represent a volitional trade by the reporting person. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 15:57 UTC | Metagenomi Therapeutics, Inc. MGX · Entity 7270 | GrantStock Option (Right to Buy) · Derivative | 22,725 | $0.00 Strike: $1.32 | $0.00 |
DisclosureSEC source: 0000950170-25-050100 · ownership.xml · derivative · entry 4 Wein Matthew · CIK 0002009713 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,725 Underlying: Common Stock · 22,725 shares Expires 2035-03-31 F3 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on April 1, 2026, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 15:57 UTC | Metagenomi Therapeutics, Inc. MGX · Entity 7270 | GrantStock Option (Right to Buy) · Derivative | 21,875 | $0.00 Strike: $1.32 | $0.00 |
DisclosureSEC source: 0000950170-25-050100 · ownership.xml · derivative · entry 3 Wein Matthew · CIK 0002009713 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,875 Underlying: Common Stock · 21,875 shares Expires 2035-03-31 F3 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on April 1, 2026, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 15:57 UTC | Metagenomi Therapeutics, Inc. MGX · Entity 7270 | GrantCommon Stock | 3,775 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-050100 · ownership.xml · nonDerivative · entry 2 Wein Matthew · CIK 0002009713 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,892 F2 · shares: These shares represent restricted stock units ("RSUs"). 25% of the RSUs shall vest on March 5, 2026, with the remainder vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 15:57 UTC | Metagenomi Therapeutics, Inc. MGX · Entity 7270 | GrantCommon Stock | 3,650 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-050100 · ownership.xml · nonDerivative · entry 1 Wein Matthew · CIK 0002009713 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,117 F1 · shares: These shares represent restricted stock units ("RSUs"). 25% of the RSUs shall vest on June 5, 2026, with the remainder vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 21:38 UTC | Metagenomi Therapeutics, Inc. MGX · Entity 7270 | SaleCommon Stock | 930 | $1.87 | $1,743.56 |
DisclosureSEC source: 0000950170-25-035566 · ownership.xml · nonDerivative · entry 1 Wein Matthew · CIK 0002009713 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,467 F1 · kind: These shares of common stock were automatically sold for the purpose of satisfying the reporting person's tax withholding obligations upon the vesting of certain restricted stock units granted to the reporting person on April 1, 2024, and does not represent a volitional trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $1.85 to $1.90, inclusive. The reporting person undertakes to provide to Metagenomi, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 01, 2024 Filed Apr 4, 2024 00:57 UTC | Metagenomi Therapeutics, Inc. MGX · Entity 7270 | GrantStock Option (Right to Buy) · Derivative | 43,717 | $0.00 Strike: $10.82 | $0.00 |
DisclosureSEC source: 0000950170-24-041545 · ownership.xml · derivative · entry 2 Wein Matthew · CIK 0002009713 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,717 Underlying: Common Stock · 43,717 shares Expires 2034-03-31 F2 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on February 1, 2025, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date. Read SEC document |
| April 01, 2024 Filed Apr 4, 2024 00:57 UTC | Metagenomi Therapeutics, Inc. MGX · Entity 7270 | GrantCommon Stock | 10,397 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-041545 · ownership.xml · nonDerivative · entry 1 Wein Matthew · CIK 0002009713 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,397 F1 · shares: These shares represent restricted stock units ("RSUs"). 25% of the RSUs shall vest on March 5, 2025, with the remainder vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.